Dr. Nicole Lounsbury,
Dr. Lounsbury’s research interests are in the discovery and development of novel pharmaceuticals. Her academic research experience was focused on the design of novel antimicrobials for methicillin-resistant S. aureus and chalcone activators of Nrf2. Her research interests also include the development of inhibitors of CXCR7 for the treatment of lung cancer.
Boylan, P.M.; Sedlacek, J.; Santibanez, M.; Church, A.F.; Lounsbury, N.; Nguyen, J. Development and Implementation of Interprofessional Relations Between a College of Pharmacy and Osteopathic Residency Programs in a Community Teaching Hospital. Journal of Pharmacy Technology. 2019, 36, 3-9.
Lounsbury, N.; Eidem, T.; Colquhoun, J.; Mateo, G.; Abou-Gharbia, M.; Dunman, P.M.; Childers, W. Novel inhibitors of Staphylococcus aureus RnpA that synergize with mupirocin. Bioorgan Med Chem Lett. 2018, 28, 1127-1131.
Kurimchak AM, Shelton C, Duncan KE, Johnson KJ, Brown J, O’Brien S, Gabbasov R, Fink LS, Li Y, Lounsbury N, Abou-Gharbia M, Childers WE, Connolly DC, Chernoff J, Peterson JR, Duncan JS. Resistance to BET bromodomain inhibitors is mediated by kinome reprogramming in ovarian cancer. Cell Reports 16: 1273-1286 (2016)
Lounsbury N, Mateo G, Jones B, Papaiahgari S, Thimmulappa RK, Teijaro C, Gordon J, Korzekwa K, Ye M, Allaway G, Abou-Gharbia M, Biswal S, Childers W. Heterocyclic chalcone activators of nuclear factor (eryhtoid-derived 2)-like 2 (Nrf2) with improved in vivo efficacy. Bioorganic and Medicinal Chemistry 23: 5352-5359 (2015)
Eidem, TM, Lounsbury N, Emery JF, Bulger J, Smith A, Abou-Gharbia M, Childers W, Dunman PM. Small molecule inhibitors of Staphylococcus aureus RnpA-mediated RNA turnover and tRNA processing. Antimicrobial Agents and Chemotherapy 59: 2016-2028 (2015)